INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed Stephen Hordley

Dated 14 July 2003

Patent Form 1/77

Pa[illegible]ct 1977
([illegible])

THE PATENT OFFICE
G
19 APR 2002
NEWPORT

The Patent Office

1/77

Request for grant of a patent

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference — P30323-/GMM/PMC/MEA

19 APR 2002

2. Patent Application Number *(the Patent Office will fill in this part)* — 0208945.6

19APR02 E712334-4 D02884
P01/7700 0.00-0208945.6

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

The Queen's University of Belfast
University Road
Belfast
BT7 1NN
Northern Ireland

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give the country/state of its incorporation

8896075001

4. Title of the invention

"Vascular Impedance Measurement Apparatus"

5. Name of your agent *(if you have one)*

Murgitroyd & Company

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

Scotland House
165-169 Scotland Street
GLASGOW
G5 8PL

Patents ADP number *(if you know it)*

1198013

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

atents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	-
Description	15
Claim(s)	-
Abstract	-
Drawing(s)	2 + 2

). If you are also filing any of the following, State how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	-
Request for preliminary examination and search *(Patents Form 9/77)*	-
Request for substantive examination *(Patents Form 10/77)*	-
Any other document (please specify)	-

I/We request the grant of a patent on the basis of this application

Signature Murgitroyd & Co. Date 18 April 2002

Murgitroyd & Company

2. Name and daytime telephone number of person to contact in the United Kingdom — Mark Earnshaw 0141 307 8400

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication publication or communication has been given, or any such direction has been revoked.

Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

Write your answers in capital letters using black ink or you may type them.

If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

If you have answered 'Yes' Patents Form 7/77 will need to be filed.

Vascular Impedance Measurement Apparatus

Introduction

The present invention relates to apparatus for measuring vascular impedance.

The complications of cardiovascular disease represent the leading cause of morbid and mortal events in Western society. At present, diagnostic procedures are designed to assess the extent and severity of blood vessel damage when symptoms present or with the occurrence of vascular events. The diagnostic challenge is to detect abnormal structure and function in the vascular system at an early pre-clinical stage. The ability to detect and monitor sub-clinical arterial damage has the potential to refine cardiovascular risk stratification and enable early intervention to prevent or attenuate disease progression.

Traditionally, the arterial circulation has been considered a steady-flow system characterised by mean arterial pressure that represents the product of cardiac output and total peripheral resistance.

The pulsatile component of pressure is determined by the pattern of left ventricular ejection and the stroke volume. The compliance characteristics of the arterial circulation has been largely ignored in prior haemodynamic studies.

The importance of assessing arterial wall integrity has been highlighted by studies demonstrating that a reduction in the pulsatile function or compliance characteristics of large arteries represents a powerful independent risk factor for future cardiovascular events. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in disease processes associated with increased cardiovascular risk. Importantly, impaired pulsatile arterial function is recognised as an independent predictor of risk for vascular events in patients with various disease states including coronary heart disease, congestive heart failure, hypertension and diabetes mellitus.

Studies relating outcome to abnormalities in pulsatile function have focused on large arteries, although analysis of arterial pressure pulse waveforms suggest that the earliest abnormalities in

arterial structure and function resides in the microcirculation.

The study of this section of the vasculature has been hindered by the lack of a non-invasive, reproducible and repeatable technique capable of assessing the compliance characteristics or pulsatile function of small arteries and arterioles.

Physiologically, the impedance load or opposition to flow presented by the circulation is measured invasively by analysing the altered pressure/flow relationships and pulse contour parameters produced through the effects of disease on the structural and functional components of the arterial system. Input impedance relates simultaneously recorded pressure and flow waveforms under specific mathematical conditions. The haemodynamic properties of the system can be quantified as the impedance concept permits the heart and arteries to be considered separately and their interaction understood as a function of pump and load properties. As pressure and flow waves are periodic and continuous, Fourier series methods can be used to generate the impedance function. The modulus at each harmonic in the Fourier series is the ratio of the pressure modulus to the flow modulus at that harmonic and the phase at each harmonic is the difference between pressure phase and flow phase at the same harmonic. As the impedance of a vascular bed varies with frequency, complete specification of pulsatile pressure and

flow relationships takes the form of the spectrum of moduli and phase angles versus frequency[5].

Characteristic impedance (the inverse of arterial compliance) defines the relationship between pressure and flow in an artery or arterial network when pressure and flow waves are not influenced by wave reflections. These conditions do not exist in the arterial system and the input impedance values oscillate around the characteristic impedance value because of wave reflection. Wave reflections are known to exert their greatest influence on impedance moduli at low frequencies. For higher frequencies, the input impedance approaches the characteristic impedance which has been estimated in prior haemodynamic studies as the arithmetic mean of input impedance moduli above 2-4 Hz.

In the prior art, detailed studies of arterial pressure and flow are only possible through the use of invasive techniques. Such techniques cannot be used to monitor changes in the circulatory system of a patient over time because of the dangers to health posed by these techniques.

Statements of Invention

In accordance with a first aspect of the present invention there is provided apparatus for the measurement of vascular impedance of the ocular micro circulation *in vivo*, the apparatus comprising intra-ocular pressure measurement means, from which

a pressure pulse waveform is calculable and blood velocity profile measurement means for measuring the linear blood flow velocity in the retrobulbar circulation, means for calculating the vascular impedance modulus from the pressure pulse waveform and the linear blood flow velocity .

Preferably the arterial pulse waveform measurement means measures the maximum and minimum pressure values of the pulse profile to calculate a mean intra-ocular pressure.

Preferably, an ocular pneumotonometer is used to measure intra-ocular pressure.

Preferably the blood velocity profile measurement means is an ultrasound device.

Preferably the ultrasound device is a doppler ultrasound imager.

Preferably the change in the pulsatile intra-ocular pressure waveform and the linear blood flow velocity are measured sequentially.

Preferably, the means for calculating the vascular impedance modulus comprises obtaining the fourier transform of the intra-ocular pressure pulse waveform and the linear blood flow velocity and dividing the transformed values of the pulsatile change in the intra-ocular pressure pulse by the transformed retrobulbar blood flow velocity.

Preferably the pulsatile change in intra-ocular pressure has a phase associated therewith.

Preferably the intra-ocular blood velocity has a phase associated therewith.

In accordance with a second aspect of the present invention there is provided a method for the measurement of vascular impedance of the ocular micro circulation *in vivo*, the method comprising the steps of: measuring the intra-ocular pressure pulse waveform of the ocular network;
measuring the linear blood flow velocity in the retrobulbar circulation; and
calculating the vascular impedance modulus from the intra ocular pressure pulse waveform and the linear blood flow velocity waveform.

Preferably, the change in the pulsatile intra-ocular pressure waveform and the linear blood flow velocity are measured sequentially.

Specific Description

The invention will now be described by way of example only with reference to the accompanying drawings in which:

Fig.1 is a diagram of an eye having means for measuring the intra-ocular pressure using the

principle of applanation tonometry at the front of the eye;

Fig.2 is a diagram of an eye having means for measuring the linear flow velocity by interrogating the retrobulbar circulation from the front of the eye;

Fig.3 is a graph of the periodic pressure signal as measured using the present invention plotted against time;

Fig.4 is a graph of the periodic velocity signal as measured using the present invention plotted against time;

Fig.5 is a graph of impedance modulus plotted against frequency; and

Fig.6 is a graph of phase plotted against frequency.

Figs. 1 and 2 show a first embodiment of the present invention. Figs.1 and 2 are diagrams showing some features of the human eye 1. These include the optic nerve 3, the ophthalmic artery 5, a bolus of blood contained in the ophthalmic artery 5 positioned outside the ocular vascular network 9. The vein 11 is also shown.

Fig.1 also shows the means for measuring the intra-ocular pressure 13, provided, in this example by a tonometer system applanated to the cornea 23.

Fig.2 shows means for measuring the linear blood flow velocity in the retrobulbar circulation 17, connected to the front of the eye. This is an ultrasonic device that is placed on the eyelid 19,the eyelid 19 being covered with a gel 21 to ensure that the ultrasound device is properly coupled to the eye 1. This device measures the linear velocity of the bolus of blood 7 in the ophthalmic artery 5.

In use, the tonometer system 13 employs continuous airflow pneumotonometry with a probe 15 applanated on the cornea to record intraocular pressure using a pneumatic sensor. The device samples at 200 Hz with a resolution of 0.01 mmHg and the signals are acquired over a 20 second period. Pulsatile variation of intraocular pressure results from pressure oscillations generated by cardiac contraction altering the distending pressure in the vessel walls. Compliance of an artery, or an entire arterial bed, describes the ability to store a varying amount of blood. Changes in volume within the ocular vascular bed will produce an equal change in volume. The pulsatile ocular waveforms are recorded after administration of oxybuprocaine 0.4% drops to anaesthetise the cornea.

The variation in intra-ocular pressure as a function of time reflects the introduction of the bolus of blood 7 into the ocular vascular network 9. The

ocular vascular network 9 expands to accommodate the additional volume of blood.

As the intra-ocular fluids are incompressible, the intra-ocular pressure response to the volume change will depend of the viscoelastic properties of the vessel network and the ocular rigidity. The mechanical properties and distending pressures will vary at different sites in the ocular vascular network 9 and it is the composite effect of these influences that determine the intra-ocular pressure waveform morphology. Whilst the rigidity of the ocular coat can vary between individuals, the half-life of the collagen and elastin components are measured in years. Consequently, the characteristics of these boundary structures would not be expected to change significantly within an individual over a period of weeks or months. Therefore changes recorded in the intra-ocular pressure pulse waveform will be reflective of alteration in the viscoelastic properties of the ocular microcirculatory bed.

The present invention uses the directly recorded change in intra-ocular pressure in its analysis and not the generated flow output measurements from the device that relate pressure change to volume change within the eye. The pulsatility of the intra-ocular pressure is dependent on the pulsatile inflow and distension of the vessels which is related to the viscoelastic properties of the ocular circulation. Scleral rigidity may limit the frequency of pressure

fluctuations but does not cause variation in pressure.

In the example shown in Fig.2, a colour doppler ultrasound imager 17 is used to examine the blood velocity waveform in the retrobulbar ocular circulation. This technique employs simultaneous B-scan and doppler imaging to allow location and identification of blood vessels. The sample volume defined by the imager 17 is placed over a vessel of interest, in this case, the bolus of blood 7 and the frequency shifts received are assembled into a spectral waveform. The spectral waveform represents the cumulative frequency shifts present and can be displayed as a time-velocity waveform.

In use, alternate measurements of the arterial pulse waveform and blood velocity profile are taken. The shape of the linear velocity flow waveform, recorded in the retrobulbar circulation , is determined by and is critically dependent on changes in total cross-sectional area of the ocular vascular network.

Like pressure, flow will also vary at different sites in the ocular vascular network 9 and the velocity waveform morphology therefore reflects the status of the entire ocular vascular network 9. In essence, the flow velocity waveform derived from the retrobulbar circulation and the intra-ocular pressure waveform reflect the sum total of the

various calibre and pressure changes throughout the ocular vascular bed.

Measured over time, changes in the linear flow waveform can provide information on changes in the ability of the ocular vascular network to expand during the cardiac cycle. Such information can lead to early diagnosis and subsequent early treatment of disease.

The present invention uses linear velocity of flow in calculating the vascular impedance of the microcirculation as changes in velocity of flow are determined by changes in the total cross-sectional area of the ocular vascular network 9. Furthermore, the use of linear velocity of flow permits comparisons of impedance moduli derived from different arteries and in the same artery under varying conditions. This comparison cannot be validly made using volume flow measurements.

Typical examples of intraocular pressure and velocity profiles (obtained from the ophthalmic artery) are shown in Figures 3 and 4.

Fig. 3 is a graph of pressure plotted with respect to time. The figure shows the periodicity of the pressure fluctuation. The cardiac cycle can be identified from the period of the pressure fluctuation as being approximately 0.9 s.

Fig. 4 is a graph of linear blood velocity plotted with respect to time. The figure shows the

periodicity of linear velocity fluctuation. The cardiac cycle can be identified from the period of the linear velocity fluctuation as being approximately 0.9s.

The sites of data acquisition enable the recording of pressure and linear velocity waveforms that provide information about the entire ocular vascular network and not merely single vessel in the network. Measurements are obtained sequentially using the tangent method to align pressure and velocity waveforms. This technique is employed to ensure effective alignment of waveforms for analysis. The signals may also be gated to an ECG. Other known methods may also be employed.

As seen in Figures 3 and 4, the velocity and pressure signals are periodic and time dependent and can thus be represented in the frequency domain by obtaining their Fourier transform: $P(\omega) = FT\ [P(t)]$ and $V(\omega) = FT[V(t)]$ where FT represents Fourier transformation. In addition, each frequency component of pressure and velocity will have its own associated phase ($\emptyset p$ pressure phase, $\emptyset v$ velocity phase). The frequency dependent impedance modulus and phase can be determined from: $Z(\omega) = P(\omega)/V(\omega)$ and $\emptyset(\omega) = \emptyset p(\omega) - \emptyset V(\omega)$.

Figures 5 and 6 show typical plots of $Z(\omega)$ and $\emptyset(\omega)$ for a normal subject.

The flow and first derivative of pressure occur at similar time points. As pressure and flow are obtained sequentially the first derivative of the pressure waveform is aligned to the flow waveform. A tangent to end diastole and a tangent to the initial upstroke in pressure wall intersect at the "foot" of the waveform. This point is aligned with the same point on the flow waveform.

Frequency domain analysis provides information about steady-state (resistance) and pulsatile function (characteristic impedance) of the ocular circulation. In Fig. 5, the steady state resistance is shown in area A and the characteristic impedance in area B. These signals are stored in digital form and the digitised signals are amenable to analysis in the time domain with the application of mathematical models to interpret waveshape changes in relation to the mechanical properties of the ocular circulatory bed.

The present invention is highly advantageous with respect to the prior art because it provides a non-invasive method and apparatus for measuring vascular impedance and in particular, through interrogation of the wave shape, of the linear velocity profile of the blood bolus in the retrobulbar circulation. Previously, invasive techniques had only been thought capable of providing information on the linear velocity profile. Such techniques are expensive and cannot be used to obtain repeat results over a period of time for the same subject.

The present invention therefore allows a physician to monitor changes in the microcirculation of the eye and to extrapolate the data to make clinical judgements in various disease states associated with an increase in cardiovascular events.

The present invention is applicable in a number of areas of clinical research. Some examples are given below.

It has been recognised for many years that characteristic changes in the arterial pressure pulse contour occur in many disease states and with physiological and pharmacological interventions. Alteration in arterial waveform morphology typically involves a steepening of the diastolic decay and a diminution in the amplitude and duration of the oscillatory waveform that distorts the proximal part of diastole from a pure monoexponential. The oscillatory diastolic waveform arises from wave reflection and damped resonance occurring in the arterial tree with the major sites of reflected waves originating in smaller arteries and arterioles. Loss of the oscillatory diastolic waveform is recognised as an early marker of altered vessel wall properties that identifies impaired pulsatile function of arteries as it can be found in patients at increased cardiovascular risk without alteration in total peripheral resistance. This has been demonstrated in patients with diabetes mellitus and cigarette smokers. Whilst the microvascular changes associated with diabetes are well

recognised, the structural changes that are commonly found in the arterioles of smokers and rarely in non-smokers, are less well appreciated. These microvascular abnormalities may account for the common occurrence of microinfarcts found in association with diabetes and cigarette smoking that have hitherto gone unrecognised.

Analysis of the arterial pressure pulse waveform can also be useful in identifying the haemodynamic action of drug therapy not detected by the traditional measurement of peripheral resistance.

Improvements and modifications may be incorporated herein without deviating from the scope of the invention.



Fig. 1



Fig. 2



Fig-3



Fig. 4

A



B

Fig. 5



Fig. 6